Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535326 | 0.87 | PRKDC (0.47) | LMNAPRKDCTUBB1ERN1MAPT | |
| SCHEMBL29053405 | 0.84 | LMNA (0.41) | LMNAPRKDCTUBB1ERN1MAPT | |
| SCHEMBL19810795 | 0.84 | LMNA (0.49) | LMNAPRKDCTUBB1ERN1MAPT | |
| SCHEMBL2605834 | 0.83 | BACE1 (0.34) | LMNATUBB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL289027 | 0.83 | LMNA (0.59) | LMNAPRKDCTUBB1ERN1MAPT | |
| SCHEMBL16341868 | 0.81 | TUBB1 (0.42) | TUBB1ERN1MAPTALDH1A1HPGD | |
| SCHEMBL16705703 | 0.81 | TUBB1 (0.52) | LMNATUBB1ERN1MAPTALDH1A1 | |
| SCHEMBL584683 | 0.80 | ERN1 (0.61) | LMNAPRKDCERN1MAPTALDH1A1 | |
| SCHEMBL7661459 | 0.80 | CA12 (0.47) | LMNAPRKDCTUBB1ERN1MAPT | |
| SCHEMBL1185798 | 0.80 | ERN1 (0.67) | TUBB1ERN1TRIM24TYRTRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| CN-105884758-B | Tricyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2019-12-10 | — | — | CN | disclosed |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| CN-102046575-A | Therapeutic agent for alzheimer's disease | TOKYO INST TECH | 2011-05-04 | — | — | CN | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
| CN-101952280-A | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO | 2011-01-19 | — | — | CN | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | LMNA 1633/4885PRKDC 4795/4885TUBB1 871/4885 |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | LMNA 1964/4885PRKDC 4840/4885TUBB1 2276/4885 |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | LMNA 3481/4885PRKDC 3413/4885TUBB1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.